UNTERNEHMENSDATEN
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a nov …
KURSVERLAUF
1T
-3,7 %
1W
-15,2 %
1M
-20 %
6M
+109,2 %
YTD
+139,1 %
1J
+130,5 %
2J
-30,6 %
5J
-85,2 %
10J
-87,4 %
FRAG DIE AGENTEN ZU MGNX
Keine Anlageberatung. Für die vollständige Analyse-Übersicht: zur Analyse-Seite →
ANALYSTEN-EINSCHÄTZUNG
KURSZIEL TIEF
6,00 $
KONSENS
6,00 $
MEDIAN
6,00 $
KURSZIEL HOCH
6,00 $
0
STRONG BUY
12
BUY
9
HOLD
1
SELL
0
STRONG SELL
22
GESAMT · Buy
| DATUM | ANALYSTENHAUS | RATING | AKTION |
|---|---|---|---|
| 20.04.2026 | Barclays | Overweight | maintain |
| 10.04.2026 | B. Riley Securities | Neutral → Buy | upgrade |
| 10.03.2026 | Barclays | Overweight | maintain |
| 03.11.2025 | HC Wainwright & Co. | Neutral | maintain |
| 15.08.2025 | Leerink Partners | Outperform | maintain |
| 20.05.2025 | B. Riley Securities | Neutral | maintain |
| 14.05.2025 | Barclays | Overweight | maintain |
| 14.05.2025 | Stifel | Hold | maintain |
KENNZAHLEN
KGV
-3,5
KBV
11,52
EV/EBITDA
-4,24
EIGENKAPITALRENDITE
-173,5 %
NETTOMARGE
-177 %
VERSCHULDUNG (D/E)
1,72
DIVIDENDENRENDITE
0 %
STAND
31.03.2026
FREE FLOAT & LIQUIDITÄT
STREUBESITZ
87,9 %
AKTIEN IM STREUBESITZ
55.877.070
Ø TAGESVOLUMEN (30T)
1.234.631
INVESTIERTE FONDS
| FONDS / INSTITUTION | ANTEILE | VERÄNDERUNG | STAND |
|---|---|---|---|
| Sound Income Strategies, LLC | 0 | -7.262 | 30.06.2026 |
| SANDERS MORRIS HARRIS LLC | 0 | -12.345 | 30.06.2026 |
| ARMISTICE CAPITAL, LLC | 6.012.000 | -312.000 | 31.03.2026 |
| RENAISSANCE TECHNOLOGIES LLC | 2.963.559 | +54.928 | 31.03.2026 |
| MILLENNIUM MANAGEMENT LLC | 2.794.357 | +819.877 | 31.03.2026 |
Keine Anlageberatung. Vergangene Wertentwicklung ist kein Indikator für zukünftige Ergebnisse.